Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden.
Lars BernfortMagnus HusbergAnn-Britt WiréhnUlf RosenqvistStaffan GustavssonKristina KarlsdotterLars-Åke LevinPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2020)
Empagliflozin treatment would reduce mortality and healthcare utilization in the patient group. The treatment strategy should be considered cost-effective, supporting a broad implementation of empagliflozin for patients with T2D and established CVD, in line with current national and international guidelines.